Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Rabesta - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Rabesta

Approved

STANDARD

Rabesta

Stallion Laboratories Pvt. Ltd.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: fc992dff736a52db
Company: Stallion Laboratories Pvt. Ltd.
Type: Standard

Approval Details

Approval Id: fc992dff736a52db
Drug Approval Philippines Name: Rabesta
Product Name: Rabesta
Registration Number: DRP-6763
Brand Name: Rabesta
Generic Name: Rabeprazole Sodium
Dosage Form: Powder for Solution for Intravenous Injection
Dosage Strength: 20 mg
Manufacturer: Stallion Laboratories Pvt. Ltd.
Importer: Ambica International Corporation
Distributor: Ambicare Pharmaceuticals Inc.
Issuance Date: 26 May 2021
Expiry Date: 20 July 2026
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

fc992dff736a52db

Type

Standard

Back to Philippines FDA Approvals